GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexon Inc (NAS:ANNX) » Definitions » Net Loan

ANNX (Annexon) Net Loan


View and export this data going back to 2020. Start your Free Trial

What is Annexon Net Loan?

Net Loan only applies to banks and insurance companies.


Annexon Business Description

Traded in Other Exchanges
N/A
Address
1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Executives
Dean Richard Artis officer: EVP & Chief Scientific Officer C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005
Jennifer Lew officer: EVP & Chief Financial Officer 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Ted Yednock officer: EVP & Chief Innovation Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Overdorf officer: EVP & Chief Business Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Douglas Love director, officer: President & CEO C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William H. Carson director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016
Muneer A Satter director C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Bain Capital Life Sciences Fund, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Larry Mattheakis officer: Chief Scientific Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Sanjay Keswani officer: EVP & Chief Medical Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Clarus Lifesciences Iii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017